VYNE_OUT_1 [2025-04-14 12:20:33 -0400] 3696 Bytes | 1014 tokens | Cum: 1014 tkns (12.68% of 8k)
==========================================================================

Booyah, my friends! It's already 12:20:32 PM on Mon Apr 14, 2025 -0400, and I've got my eyes locked on VYNE Therapeutics (VYNE), pushing up to 1.6442 from 1.5550. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: VYNE Therapeutics (VYNE)
IPO: 2018-01-25 (7 Years Ago)
Market Cap: $25,856,765
Shares Outstanding: 15,210,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Here’s the first list of news for VYNE Therapeutics:

C1 - Mar-20-25 08:00AM - VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
C2 - Mar-06-25 08:00AM - VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
C3 - Feb-20-25 08:00AM - VYNE Therapeutics to Participate in March Investor Conferences
C4 - Feb-19-25 08:00AM - VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
C5 - Jan-06-25 07:30AM - VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
C6 - Dec-24-24 09:51AM - H.C. Wainwright says VYNEs VYN202 becomes pick of the crop after MAD data
C7 - Dec-23-24 07:30AM - VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
C8 - Nov-19-24 06:15AM - VYNE Therapeutics initiated with a Buy at BTIG on I&I potential

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and report parser.
Your role is to examine all available company data and draw sound conclusions.
The company under analysis is: VYNE Therapeutics (VYNE).

2) To request information, refer to any listed documents using their reference codes.

3) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
At the end, you'll be prompted to return these data pairs:

1) BRIEF_SUMMARY[] -- Write a brief summary
2) MARKET_SCORE[] -- Assign a Market Score
3) PRICE_TARGET[] -- Set a price target
4) AI_RPT_HEADLINE[] -- Generate a headline for the article
5) SQUEEZE_POTENTIAL[] -- Potential for this stock to become an active short squeeze play
6) TAGS[] -- 1 to 4 words for SEO tags
7) STOCK_TYPE[] -- Describe the type of investor style suited to this stock
8) PRIMARY_CATALYST[] -- What you believe caused this stock to move today
9) SENTIMENT[] -- Mkt sentiment of the opportunity
10) IMPROVEMENT_SUGGESTION[] -- What can we do better
11) ETHICAL_RATING[] -- Rate alignment with long-term shareholder interests

Restrict the next response to just 3 tokes until it's time for the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

VYNE_OUT_3 [2025-04-14 12:20:35 -0400] 1109 Bytes | 326 tokens | Cum: 1342 tkns (16.78% of 8k)
==========================================================================

Showing C2 (chunk 1 of 9): C2:
**VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update**
Date: Mar-06-25 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/06/3038147/0/en/VYNE-Therapeutics-Reports-2024-Fourth-Quarter-and-Year-End-Financial-Results-and-Provides-Business-Update.html

March 06, 2025 08:00 ET| Source:VYNE Therapeutics Inc.VYNE Therapeutics Inc.

BRIDGEWATER, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the fourth quarter and year ended December 31, 2024, and provided a business update.

“Based on our significant progress in 2024, we a

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

VYNE_OUT_5 [2025-04-14 12:20:35 -0400] 1105 Bytes | 298 tokens | Cum: 1642 tkns (20.52% of 8k)
==========================================================================

Showing C2 (chunk 2 of 9): re now positioned to announce two key data readouts for repibresib gel and VYN202 in 2025,” said David Domzalski, President and Chief Executive Officer of VYNE. “We are off to a strong start in 2025. In January, we announced the completion of enrollment in the Phase 2b trial of our locally administered pan-BD BET inhibitor, repibresib, in nonsegmental vitiligo, and we expect to report topline results in mid-2025. We also recently initiated the Phase 1b trial of our oral BD2-selective BET inhibitor, VYN202, in subjects with moderate-to-severe plaque psoriasis, and we anticipate reporting topline results from this trial by the end of this year.”

Repibresib gel (VYN201), a locally-administered small molecule pan-BD BET inhibitor (Phase 2b, nonsegmental vitiligo):

VYN202, an oral small molecule BD2-selective inhibitor:

Financial Results as of and for the Year EndedDecember 31, 2024

Cash

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

VYNE_OUT_7 [2025-04-14 12:20:37 -0400] 1107 Bytes | 290 tokens | Cum: 1934 tkns (24.18% of 8k)
==========================================================================

Showing C2 (chunk 3 of 9): position.As of December 31, 2024, VYNE had $61.5 million of cash, cash equivalents and marketable securities. Based on current operating assumptions, VYNE believes its cash, cash equivalents and marketable securities as of December 31, 2024 will be sufficient to fund its operations into the second half of 2026.

Share count.As of December 31, 2024, VYNE had 14,830,013 common shares issued and outstanding, and outstanding pre-funded warrants to purchase 27,842,740 shares of common stock at an exercise price of $0.0001 per share.

Revenues.Revenues totaled $0.5 million and $0.4 million for the years ended December 31, 2024 and 2023, respectively, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma A/S, to whom VYNE previously licensed the rights to Finacea®foam.

Research and development expenses. VYNE’s research and development expenses for the years ended D

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

VYNE_OUT_9 [2025-04-14 12:20:40 -0400] 968 Bytes | 289 tokens | Cum: 2225 tkns (27.81% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-08T20:27:38Z - Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer...
A2 - 2025-04-08T20:05:14Z - Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer...
A3 - 2025-04-08T20:15:24Z - Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer | Taiwan News | A...
A4 - 2025-04-08T20:15:07Z - Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer...
A5 - 2025-04-01T14:53:12Z - Phathom Pharmaceuticals, Inc. Announces Management Changes, Effective April 1, 2025...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

VYNE_OUT_11 [2025-04-14 12:20:42 -0400] 1099 Bytes | 307 tokens | Cum: 2534 tkns (31.67% of 8k)
==========================================================================

Showing A1 (chunk 1 of 12): A1:
**Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer**Date: 2025-04-08Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/09/tmt-newswire/globenewswire/artiva-biotherapeutics-appoints-subhashis-banerjee-md-as-chief-medical-officer/2088865Mama's Creations Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy

SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerj

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

VYNE_OUT_13 [2025-04-14 12:20:43 -0400] 894 Bytes | 301 tokens | Cum: 2899 tkns (36.24% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-06-26T12:00:00Z - VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
B2 - 2024-06-14T13:01:32Z - Analyst Scoreboard: 4 Ratings For VYNE Therapeutics
B3 - 2024-06-13T13:02:00Z - VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
B4 - 2024-05-09T13:15:05Z - VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
B5 - 2024-05-08T12:10:07Z - Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
B6 - 2024-03-13T13:55:03Z - Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

VYNE_OUT_15 [2025-04-14 12:20:47 -0400] 626 Bytes | 189 tokens | Cum: 3090 tkns (38.62% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/06/26/2904448/0/en/VYNE-Therapeutics-to-Participate-in-Leerink-Partners-Therapeutics-Forum.htmlBoston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

VYNE_OUT_17 [2025-04-14 12:20:48 -0400] 791 Bytes | 203 tokens | Cum: 3412 tkns (42.65% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S5 - 2025-03-06 10-K ITEM 7 - MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included ...

S6 - 2025-03-06 8-K Item 2.02 Results of Oper and Fin Cond.

On March 6, 2025, VYNE Therapeutics Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2024. The press release is being furnished as Exhibit 99.1 to this Curr ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

VYNE_OUT_19 [2025-04-14 12:20:50 -0400] 1098 Bytes | 231 tokens | Cum: 3645 tkns (45.56% of 8k)
==========================================================================

Showing S5 (chunk 1 of 6): S5:
ITEM 7 - MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Annual Report on Form 10-K. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report on Form 10-K, particularly in the section entitled Item 1A. Risk Factors.

Company Overview

We are a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-media

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

VYNE_OUT_21 [2025-04-14 12:20:52 -0400] 1098 Bytes | 258 tokens | Cum: 3905 tkns (48.81% of 8k)
==========================================================================

Showing S5 (chunk 2 of 6): ted conditions with high unmet need.

We have exclusive worldwide rights to research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in humans, which we licensed from Tay Therapeutics Ltd., formerly known as In4Derm Ltd ("Tay"). BET proteins are epigenetic enablers of transcription that regulate the expression of specific genes. Each BET protein consists of two bromodomains (BD1 and BD2) and one end terminal (ET) domain. Through our transaction with Tay, we obtained access to a library of new small molecule BET inhibitor compounds including those that inhibit both BD1 and BD2 (pan-BD BET inhibitor) and that selectively inhibit BD2 (BD2-selective BET inhibitor). Through our access to this library of new BET inhibitors, which comprise our InhiBET portfolio, we plan

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

VYNE_OUT_23 [2025-04-14 12:20:53 -0400] 1098 Bytes | 235 tokens | Cum: 4226 tkns (52.83% of 8k)
==========================================================================

Showing S5 (chunk 3 of 6): to develop product candidates for a diverse set of therapeutic indications. We have chosen to initially focus our development efforts with these molecules on immune-mediated inflammatory diseases, which are not being targeted by current BET inhibitors in development.

Our lead program is repibresib gel (also known as VYN201), a topically administered, small molecule pan-BD BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. In preclinical testing, repibresib produced consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic preclinical models. In November 2022, we initiated a Phase 1 clinical trial evaluating a topical formulation of repibresib first in healthy volunteers (Phase 1a)

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

VYNE_OUT_25 [2025-04-14 12:21:03 -0400] 7600 Bytes | 2101 tokens | Cum: 6329 tkns (79.11% of 8k)
==========================================================================

This is our set of metrics for VYNE Therapeutics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-------------------------+
| Volume: 87,769 | Perf Month: -8.38% | Option/Short: No / Yes | Sales Y/Y TTM: 18.16% |
+---------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 126.97K | Perf Quarter: -43.87% | Short Float: 1.07% | ROE: -56.54% |
+---------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 1.64 | Index: - | Short Ratio: 1.07 | ROI: -76.44% |
+---------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 46.05 | Market Cap: 25.78M | Short Interest: 0.14M | Sales Surprise: -44.00% |
+---------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 0.19 | Shs Outstand: 14.83M | Beta: 1.70 | EPS Surprise: 7.68% |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA20: 2.76% | Shs Float: 12.68M | Sales Q/Q: 10.53% | P/E: - |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA50: -18.24% | Inst Own: 48.02% | Sales past 5Y: 900.31% | Earnings: Mar 06 BMO |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA200: -25.69% | Insider Own: 16.66% | Employees: 13 | |
+---------------------+-----------------------+------------------------+-------------------------+
| Perf Week: 10.06% | Insider Trans: 0.60% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading by VYNE Therapeutics officers or majority shareholders (if available).

Inside Trans: VYNE Therapeutics Inc. (VYNE) by Domzalski David (PRESIDENT AND CEO) on 2025-03-31
- Common Stock: 30498 shares at $1.58 (D) Footnote: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

Inside Trans: VYNE Therapeutics Inc. (VYNE) by Harsch Mutya (CHIEF LEGAL OFFICER AND GC) on 2025-03-31
- Common Stock: 8828 shares at $1.58 (D) Footnote: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

Inside Trans: VYNE Therapeutics Inc. (VYNE) by Stuart Iain (CHIEF SCIENTIFIC OFFICER) on 2025-03-31
- Common Stock: 6044 shares at $1.58 (D) Footnote: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

Inside Trans: VYNE Therapeutics Inc. (VYNE) by Zeronda Tyler (CHIEF FINANCIAL OFFICER) on 2025-03-31
- Common Stock: 8399 shares at $1.58 (D) Footnote: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

Inside Trans: VYNE Therapeutics Inc. (VYNE) by Domzalski David (PRESIDENT AND CEO) on 2025-01-21
- Stock Option (right to buy): 730000 shares at $0 (D)

Inside Trans: VYNE Therapeutics Inc. (VYNE) by Harsch Mutya (CHIEF LEGAL OFFICER AND GC) on 2025-01-21
- Stock Option (right to buy): 230000 shares at $0 (D)

Inside Trans: VYNE Therapeutics Inc. (VYNE) by Stuart Iain (CHIEF SCIENTIFIC OFFICER) on 2025-01-21
- Stock Option (right to buy): 230000 shares at $0 (D)

Inside Trans: VYNE Therapeutics Inc. (VYNE) by Zeronda Tyler (CHIEF FINANCIAL OFFICER) on 2025-01-21
- Stock Option (right to buy): 230000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 501000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -39834000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.6442
Average Volume: 210107.76
30-Day High: 1.87
30-Day Low: 1.48

[Detailed Financials: TTM 2024]
- Total Assets: $66,905,000.0
- Total Liabilities: $14,819,000.0
- Total Equity: $52,086,000.0
- Current Assets: $64,437,000.0
- Current Liabilities: $14,819,000.0

[Income Statement: TTM 2024]
- Revenue: $501,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.93

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-10,748,000.0

[Detailed Financials: FY 2024]
- Total Assets: $66,905,000.0
- Total Liabilities: $14,819,000.0
- Total Equity: $52,086,000.0
- Current Assets: $64,437,000.0
- Current Liabilities: $14,819,000.0

[Income Statement: FY 2024]
- Revenue: $501,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.93

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-10,748,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of VYNE Therapeutics (VYNE).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about VYNE Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because VYNE is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for VYNE.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, VYNE could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect VYNE to increase 50% from its current price of $1.64, say: PRICE_TARGET[2.47]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of VYNE Therapeutics.

11) ETHICAL_RATING[]
Rate VYNE Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

VYNE_IN_27 [2025-04-14 12:21:04 -0400] 126 Bytes | 29 tokens | Cum: 6536 tkns (81.70% of 8k)
==========================================================================

====================================
[2025-04-14 12:21:04] # Analysis Completed
Elapsed Time: 31.58 seconds